BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Longevity therapeutics market to double by 2033
Global longevity therapeutics market projected to hit US$43.72b by 2033, as supplements and antiaging solutions move from niche…
Artificial intelligence unlocks new frontiers in RNA drug design
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in…
Scientists create light-controlled versions of cholesterol
High levels of cholesterol are linked to heart disease, stroke, and many other health problems. However, this complex…
External signals control oncolytic bacteria for precise cancer therapy delivery
Engineered oncolytic bacteria have emerged as a promising therapeutic platform for precision cancer treatment, offering tumor-specific colonization, immune…
SN101 iPSC-derived therapy relieves chronic pain and preserves joints
SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach…
Study shines new light on how cancer avoids the mitotic stopwatch pathway
When cell division (mitosis) takes too long, it can be a sign that something is wrong with the…
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…
Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows…
Global Virus Network outlines priorities as Marburg virus emerges in Ethiopia
The Global Virus Network (GVN), a coalition of leading human and animal virologists in more than 40 countries…
New signaling molecule drives development of tissue resident memory T cells
We owe a lot to tissue resident memory T cells (TRM). These specialized immune cells are among the…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…